… -pretreated patients (PPP) cohort and the EXCLAIM cohort. The PPP cohort included 114
patients with … The EXCLAIM cohort included 96 patients with previously treatedEGFRex20ins-…

… and 10% of patients with a TEAE that led to drug discontinuation. Updated efficacy information
for TKI-pretreated ROS1+ NSCLC and NTRK+ advanced solid tumor patients is being …

… In CheckMate 032, investigators evaluated tumour PD-L1 expression using the 28-8 pharmDx
antibody 47 in pretreatment tumour specimens obtained within 3 months of beginning ICI …

… with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint …
whether pretreatment NLR was associated with the outcomes of advanced NSCLC patients …

… In this retrospective study, we demonstrated that pretreatment GPS was the most robust
prognostic factor compared with mGPS and CAR in NSCLC patients treated with ICIs. This is the …

… -small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy
of the above combination therapy in previously treated patients with refractory advanced (…

… , and efficacy of sotorasib 960 mg once daily in patients with KRAS G12C-mutated, locally
advanced or metastatic non–small-cell lung cancer from the CodeBreaK 100 clinical trial (…

… The PEMBRO-RT study, a phase II randomized clinical trial that compares pembrolizumab
after SBRT with pembrolizumab alone in patients with advanced non–small cell lung cancer, …

… Non–small cell lung cancer … to assess the benefit of these treatments in patients. The
pivotal studies of OAK and POPLAR in pretreated patients support evaluation of the long-term …

… In conclusion, patients with pretreated NSCLC and high pretreatment levels of NLR (≥ 5)
and PLR (≥ 200) may experience inferior outcomes when treated with nivolumab. Therefore, …